Abstract: The present invention relates to a prefabricated wall assembly that includes an outer frame assembly and an inner frame assembly that are spaced apart from each other. The outer frame assembly includes a masonry panel composed of a plurality of masonry units such as bricks. The inner frame assembly includes an insulation panel and waterproof lining. The prefabricated wall assembly further includes sealing arrangements for allowing the prefabricated wall assembly to seal against similar adjacent prefabricated wall assemblies. The outer frame assembly includes length adjustable side support members for supporting an outer side edge of the masonry panel.

Abstract: A vessel (30) comprising a hull (15) having an apparent centre of pitch (23) located at a position between about 10% and 35% of the length of the vessel (10) measured from the aftermost point (17) of the vessel on the design waterline. The hull (15) may be bare, or alternatively may be fitted with a damping system (31) located forwardly to provide damping forces to reduce the vertical motion at the bow and hence the vertical accelerations. In one arrangement, the vessel (10) may comprise a single hull vessel. In another arrangement, the vessel (10) may comprise a multi-hulled vessel.

Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of ?3-adrenoceptor.

Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of us ing the same in the treatment or prevention of diseases mediated by the activation of ?3-adrenoceptor.

Abstract: A vessel (10) comprising a hull (15) having a the Longitudinal Centre of Flotation (LCF) at the design load waterline (25) at rest with a value of less than about 35% of the vessel waterline length measured from the aftermost point (19) of the vessel waterline. The design vessel speed at design load waterline is at or above Froude Number of 0.45. The hull (15) has a length-to-beam ratio on the design waterline of greater than about 8.0. The Longitudinal Centre of Buoyancy (LCB) is between about 30% and 45% of the vessel waterline length measured from the aftermost point (19) of the vessel waterline (25). In one arrangement, the vessel (10) may comprise a single hull vessel. In another arrangement, the vessel (10) may comprise a multi-hulled vessel.

Abstract: A vessel (30) comprising a hull (15) having an apparent centre of pitch (23) located at a position between about 10% and 35% of the length of the vessel (10) measured from the aftermost point (17) of the vessel on the design waterline. The hull (15) may be bare, or alternatively may be fitted with a damping system (31) located forwardly to provide damping forces to reduce the vertical motion at the bow and hence the vertical accelerations. In one arrangement, the vessel (10) may comprise a single hull vessel. In another arrangement, the vessel (10) may comprise a multi-hulled vessel.

Abstract: A multi-hulled vessel (10) configured as a trimaran. The multi-hulled vessel (10) comprises a main hull (15) and at least one outer hull (17) to each side of the main hull, the main hull (15) and each side hull (17) adjacent thereto being interconnected by a bridge structure (19). The bridge structure (19) and the hulls (15, 17) connected thereby cooperating to provide a deck surface (21) adapted to carry a load. The main hull 15) is configured to define at least one engine room (45) below the deck surface (21) and trunking (70) for provision of services to the engine room. The trunking (70) is routed below the area of the deck surface (21) required for carrying a load. Because the trunking (70) is routed below the area of the deck surface (21) required for load-carrying, it does not extend through that area of the deck surface to impede load movements.

Abstract: A multi-hulled vessel (10) configured as a trimaran. The multi-hulled vessel (10) comprises a main hull (15) and at least one outer hull (17) to each side of the main hull. The multi-hulled vessel (10) is provided with motion control means (40) for providing damping to wave-induced motion, thereby offering ride control. The motion control means (40) comprises a forward motion damping device (41) disposed adjacent the bow (25) of the main hull (15), and two aft dampening devices (43) disposed one adjacent the stern (33) of each side hull (17). With this arrangement, one of the motion damping devices (41, 43) is located at or near each apex of a notional triangular envelope (44) of the vessel (10). Each motion damping device (41, 43) is configured to resist wave-induced motion of the multi-hulled vessel (10) and thereby provide a damping effect. Each motion damping device (41, 43) may comprise an underwater hydrofoil (45), although other damping arrangements are possible.

Abstract: Heteroaromatic compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein ring A is: (ii-a), (ii-b), (ii-c), (ii-d), or (ii-e); and wherein n, L, M, U, X, Y, Z, RE, RF, R1, R2A, R2B, R2C, R3, R8, R9 and R10 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts and prodrugs are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts and prodrugs can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: Compounds of Formula I are described: (I), wherein RP and RQ are defined herein. The compounds transcriptase, the prophylaxis and treatment of infection by HIV, and the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: A vessel (30) comprising a hull (15) having an apparent centre of pitch (23) located at a position between about 10% and 35% of the length of the vessel (10) measured from the aftermost point (17) of the vessel on the design waterline. The hull (15) may be bare, or alternatively may be fitted with a damping system (31) located forwardly to provide damping forces to reduce the vertical motion at the bow and hence the vertical accelerations. In one arrangement, the vessel (10) may comprise a single hull vessel. In another arrangement, the vessel (10) may comprise a multi-hulled vessel.

Abstract: A vessel (10) comprising a hull (15) having a the Longitudinal Centre of Flotation (LCF) at the design load waterline (25) at rest with a value of less than about 35% of the vessel waterline length measured from the aftermost point (19) of the vessel waterline. The design vessel speed at design load waterline is at or above Froude Number of 0.45. The hull (15) has a length-to-beam ratio on the design waterline of greater than about 8.0. The Longitudinal Centre of Buoyancy (LCB) is between about 30% and 45% of the vessel waterline length measured from the aftermost point (19) of the vessel waterline (25). In one arrangement, the vessel (10) may comprise a single hull vessel. In another arrangement, the vessel (10) may comprise a multi-hulled vessel.

Abstract: A multi-hulled vessel (10) configured as a trimaran. The multi-hulled vessel (10) comprises a main hull (15) and at least one outer hull (17) to each side of the main hull, the main hull (15) and each side hull (17) adjacent thereto being interconnected by a bridge structure (19). The bridge structure (19) and the hulls (15, 17) connected thereby cooperating to provide a deck surface (21) adapted to carry a load. The main hull 15) is configured to define at least one engine room (45) below the deck surface (21) and trunking (70) for provision of services to the engine room. The trunking (70) is routed below the area of the deck surface (21) required for carrying a load. Because the trunking (70) is routed below the area of the deck surface (21) required for load-carrying, it does not extend through that area of the deck surface to impede load movements.

Abstract: A multi-hulled vessel (10) configured as a trimaran. The multi-hulled vessel (10) comprises a main hull (15) and at least one outer hull (17) to each side of the main hull. The multi-hulled vessel (10) is provided with motion control means (40) for providing damping to wave-induced motion, thereby offering ride control. The motion control means (40) comprises a forward motion damping device (41) disposed adjacent the bow (25) of the main hull (15), and two aft dampening devices (43) disposed one adjacent the stern (33) of each side hull (17). With this arrangement, one of the motion damping devices (41, 43) is located at or near each apex of a notional triangular envelope (44) of the vessel (10). Each motion damping device (41, 43) is configured to resist wave-induced motion of the multi-hulled vessel (10) and thereby provide a damping effect. Each motion damping device (41, 43) may comprise an underwater hydrofoil (45), although other damping arrangements are possible.

Abstract: Heteroaromatic compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein ring A is: (ii-a), (ii-b), (ii-c), (ii-d), or (ii-e); and wherein n, L, M, U, X, Y, Z, RE, RF, R1, R2A, R2B, R2C, R3, R8, R9 and R10 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts and prodrugs are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts and prodrugs can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: Compounds having the structure: are HIV reverse transcriptase inhibitors, wherein A, X, Y, Z, R1 and R2 are defined herein. The compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: N-(Sulfonyloxybiarylmethyl)aminocyclopropanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

Abstract: N-aryl arylsulfonamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

Abstract: Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

Abstract: N-Biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.